Studies confirm CellCept's unique survival benefits for transplant patients.
Basel, Switzerland - New data presented this week in over 70 abstracts at the American Transplant Congress in Boston, USA strengthen even further the body of evidence that CellCept® (mycophenolate mofetil, MMF) is the most reliable, efficacious, low toxic immunosuppressant for adult and paediatric kidney, heart and liver transplant patients.
The collective data presented at the ATC, in which more than 61,000 transplant patients where studied, demonstrate that CellCept-based therapies have unique benefits for solid organ transplant patients such as:
-- Proven patient survival benefits
-- Lowest toxicity profile
-- The greatest reduction in acute and chronic rejection
"In order for us to choose the best immunosuppressant regimen for our patients, we need to consider acute rejection, long term graft function, minimal toxic side-effects and, most importantly, graft and patient survival", said Prof Meier- Kriesche, University of Florida, Gainsville, FL, USA. "Long term data with meaningful patient numbers, data and experience from our peers, allows us to decide on the best low toxic combination for better outcomes and patient survival. CellCept's 10 years of clinical experience, in addition to early clinical trials, provides us that real world data", he added.
Highlights from the wealth of data presented at ATC
… in adult liver transplant patients
Lake R, Chu AH, Steffen BJ, et al. Efficacy of triple therapy with mycophenolate mofetil (MMF), tacrolimus (TACRO) and corticosteroids (CS) compared to TACRO and CS immunosuppression in liver transplantation: an analysis of the US liver transplant experience. Abstract 395, ATC 2004. CellCept reduced acute rejection rates in a study of 11,670 liver transplant patients, when added to a tacrolimus based immunosuppressant regimen. Graft and patient survival significantly improved (p
In a study of 650 heart transplant patients, a new set of data compiled by means of state of the art technology(1) shows that heart transplant patients treated with CellCept have significantly less coronary artery disease (the predominant cause of post-transplant death) than those treated with azathioprine (AZA) in the first year after heart transplantation (p